DE69333403D1 - Verfahren zur erzeugung von antikörpern gegen zelloberflächenmoleküle - Google Patents

Verfahren zur erzeugung von antikörpern gegen zelloberflächenmoleküle

Info

Publication number
DE69333403D1
DE69333403D1 DE69333403T DE69333403T DE69333403D1 DE 69333403 D1 DE69333403 D1 DE 69333403D1 DE 69333403 T DE69333403 T DE 69333403T DE 69333403 T DE69333403 T DE 69333403T DE 69333403 D1 DE69333403 D1 DE 69333403D1
Authority
DE
Germany
Prior art keywords
antibodies
antibody
cells
treat
cell surface
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69333403T
Other languages
English (en)
Other versions
DE69333403T2 (de
Inventor
Boer Mark De
B Conroy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27360277&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69333403(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US07/910,222 external-priority patent/US5397703A/en
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of DE69333403D1 publication Critical patent/DE69333403D1/de
Application granted granted Critical
Publication of DE69333403T2 publication Critical patent/DE69333403T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
DE69333403T 1992-07-09 1993-07-08 Verfahren zur erzeugung von antikörpern gegen zelloberflächenmoleküle Expired - Fee Related DE69333403T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US910222 1992-07-09
US07/910,222 US5397703A (en) 1992-07-09 1992-07-09 Method for generation of antibodies to cell surface molecules
US08/015,147 US5869050A (en) 1992-07-09 1993-02-09 Methods of blocking T-cell activation using anti-B7 monoclonal antibodies
US70158 1993-05-28
US08/070,158 US5677165A (en) 1992-07-09 1993-05-28 Anti-CD40 monoclonal antibodies capable of blocking B-cell activation
PCT/US1993/006432 WO1994001547A2 (en) 1992-07-09 1993-07-08 A method for generation of antibodies to cell surface molecules
US15147 1998-01-29

Publications (2)

Publication Number Publication Date
DE69333403D1 true DE69333403D1 (de) 2004-03-04
DE69333403T2 DE69333403T2 (de) 2004-11-11

Family

ID=27360277

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69333403T Expired - Fee Related DE69333403T2 (de) 1992-07-09 1993-07-08 Verfahren zur erzeugung von antikörpern gegen zelloberflächenmoleküle
DE69334064T Revoked DE69334064T2 (de) 1992-07-09 1993-07-08 Antagonistische monoklonale Antikörper gegen menschliches CD40

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69334064T Revoked DE69334064T2 (de) 1992-07-09 1993-07-08 Antagonistische monoklonale Antikörper gegen menschliches CD40

Country Status (5)

Country Link
EP (3) EP0651797B1 (de)
AT (2) ATE258595T1 (de)
DE (2) DE69333403T2 (de)
DK (1) DK0945465T3 (de)
ES (1) ES2273452T3 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
WO2001034649A2 (en) * 1999-11-09 2001-05-17 Chiron Corporation Compositions and methods for treating autoimmune diseases and transplant rejections
AU2001259106A1 (en) * 2000-04-19 2002-02-18 Tanox, Inc. CD40 antagonists for use in treating psoriasis and other inflammatory skin conditions
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
WO2001083755A2 (en) * 2000-04-28 2001-11-08 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
DE60143535D1 (de) * 2000-10-02 2011-01-05 Novartis Vaccines & Diagnostic Humane antikörper gegen cd40
CA2658221C (en) 2001-04-27 2012-11-27 Kyowa Hakko Kirin Co., Ltd. Anti-cd40 monoclonal antibody
DE10132308A1 (de) * 2001-07-06 2003-01-30 Aventis Behring Gmbh Kombinationspräparat zur Therapie von immunologischen Erkrankungen
WO2003028809A1 (en) * 2001-10-02 2003-04-10 Chiron Corporation Methods of therapy for b-cell malignancies
WO2003029296A1 (en) * 2001-10-02 2003-04-10 Chiron Corporation Human anti-cd40 antibodies
WO2006073443A2 (en) * 2004-04-27 2006-07-13 Novartis Vaccines And Diagnostics, Inc. Antagonist anti-cd40 monoclonal antibodies and methods for their use
EP1854810A1 (de) 2006-05-09 2007-11-14 PanGenetics B.V. De-immunisierter und antagonister monoclonaler Antikörper gegen CD40, der aus der ch5D12 Antikörper abgeleitet ist
EP3355921A4 (de) * 2015-09-30 2019-05-22 Janssen Biotech, Inc. Antagonistische antikörper, die spezifisch an menschliches cd40 binden, und verfahren zur verwendung

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000092A1 (en) * 1990-07-02 1992-01-09 Bristol-Myers Squibb Company Ligand for cd28 receptor on b cells and methods

Also Published As

Publication number Publication date
ATE339451T1 (de) 2006-10-15
DE69334064T2 (de) 2007-05-24
EP0945465B1 (de) 2006-09-13
EP0945465A1 (de) 1999-09-29
EP1834671A2 (de) 2007-09-19
DE69333403T2 (de) 2004-11-11
ATE258595T1 (de) 2004-02-15
ES2273452T3 (es) 2007-05-01
EP0651797B1 (de) 2004-01-28
EP1834671A3 (de) 2013-05-22
EP0651797A1 (de) 1995-05-10
DK0945465T3 (da) 2007-01-15
DE69334064D1 (de) 2006-10-26

Similar Documents

Publication Publication Date Title
WO1994001547A3 (en) A method for generation of antibodies to cell surface molecules
DE69333403D1 (de) Verfahren zur erzeugung von antikörpern gegen zelloberflächenmoleküle
EP0722463A4 (de) Verfahren und zusammensetzung für die modulation der wirtsimmunantwort auf allergene
TW222279B (de)
FI104047B1 (fi) DNA-molekyylejä, jotka koodaavat CD25 sitovia molekyylejä
DE69521794D1 (de) Zellen mit mehreren geänderten epitopen auf einem oberflächeantigen zur verwendung in transplantation
DE59209079D1 (de) Monoklonale Antikörper gegen humane Pankreas-Inselzellen
WO1995034581A1 (en) Inhibition of human xenogenic or allogenic antibodies to reduce xenograft or allograft rejection in human recipients
PL314414A1 (en) Antiidiotypic antibodies capable to induce an immunological response in respect to the receptor of epidermis growth factor
Dennert et al. Induction of bone marrow allograft rejection and hybrid resistance in nonresponder recipients by antibody: is there evidence for a dual receptor interaction in acute marrow graft rejection?
Hori et al. Monoclonal Antibodies against Pupa-Specific Surface Antigens ofSarcophaga peregrina (Flesh Fly) Hemocytes
DE69020914T2 (de) Monoklonale Antikörper von Ratten gegen menschliche Antigene und Verfahren zu deren Herstellung.
Mosmann et al. The high background immune reactivity of mice to polymorphic determinants on xenogeneic erythrocytes: theoretical and practical implications.
HUT75824A (en) A novel endothelial cell molecule mediating lymphocyte binding in man
Edelman THE SUBJECT AND STYLE 0F MODERN IMMUNOLOGY: AN INTRODUCTION
Mateo et al. A different method for obtaining an engineered murine antibody, that recognizes epidermal growth factor receptor, with reduced immunogenicity
De Boer et al. Method for generation of antibodies to cell surface molecules

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS,INC.(N.D.GES, US

8339 Ceased/non-payment of the annual fee